Unlocking the Mystery of Bronchiectasis Management: A Year of Breakthroughs and Controversies
Bronchiectasis, a chronic lung disease, presents a complex challenge with a heavy burden on patients and healthcare systems. This article delves into the latest real-world data and treatment guidelines, shedding light on the 'vicious vortex' of pathophysiological processes and the unmet needs in global treatment patterns.
The Year in Review: 2025
In 2025, Insmed Incorporated presented groundbreaking real-world evidence (RWE) at two major conferences: the American Thoracic Society (ATS) International Conference and the European Respiratory Society (ERS) Congress. The presentations revealed a critical need for improved treatment strategies in Non-cystic fibrosis bronchiectasis (NCFB), a heterogeneous disease with a high hospitalisation burden and exacerbations.
The ERS Clinical Practice Guideline for adult bronchiectasis management was also updated in 2025, offering a more holistic approach to diagnosis and treatment. This guideline aims to reduce exacerbations and the healthcare burden of bronchiectasis by identifying high-risk patients and recommending timely interventions.
The Complex Nature of Bronchiectasis
Bronchiectasis is a progressive inflammatory lung disease, often associated with co-morbidities like asthma and COPD, making diagnosis challenging. The pathophysiology involves a vicious vortex of inflammation, chronic airway infection, impaired mucociliary clearance, and lung damage, with neutrophils playing a key role.
But here's where it gets controversial: While the ERS guidelines recommend a multi-modal approach, focusing on symptom control and infection management, there remains a clear need for specific targeted medications. This gap highlights the ongoing struggle to effectively manage bronchiectasis and prevent complications.
Real-World Data: Unlocking Insights
Real-world data from various studies presented at ATS 2025 and ERS 2025 provide novel insights into treatment patterns, complications, and hospitalisations. These studies reveal that approximately half of NCFB patients are managed with medications, including corticosteroids and antibiotics, within 2 years of their first health insurance claim. However, complications and exacerbations remain common, indicating the need for improved management strategies.
Exacerbation Risk Factors: A Global Perspective
Exacerbations in bronchiectasis significantly impact patient quality of life and healthcare resources. Studies from the UK, France, and Japan reveal that patients with ≥2 exacerbations during baseline are at a markedly higher risk of future exacerbations. These patients often have more comorbidities and a higher treatment burden.
And this is the part most people miss: The data highlight the importance of effective strategies to reduce and manage exacerbations, especially in patients with comorbidities like asthma and COPD. However, the complexity of treating NCFB due to its heterogeneity cannot be understated.
Treatment Patterns and Challenges
A retrospective cohort study using US claims data provides new evidence on treatment patterns and complications in NCFB. The study found that commonly prescribed medications include corticosteroids, β-agonists, and antibiotics, but frequent switching of antibiotics and reliance on multiple therapies suggest current approaches may not be optimal.
Hospitalisations and Healthcare Costs
A separate retrospective study using US hospitalisation data reveals high hospitalisation rates and significant post-acute care needs for bronchiectasis patients. The study found that over a third of patients required mechanical ventilation, and approximately 17% needed intensive care, incurring substantial healthcare costs.
Updated Guidelines: A Step Forward
The 2025 ERS guidelines set new standards for bronchiectasis management, emphasizing a proactive patient-centred approach. They recommend assessing comorbidities and calculating the Bronchiectasis Severity Index (BSI) for all newly diagnosed patients to identify high-risk individuals.
Conclusion: A Call for Action
The current management of bronchiectasis is suboptimal, as evidenced by RWE showing persistent exacerbations. Increased awareness and early diagnosis are crucial, but the need for targeted medications remains a pressing issue. The controversy lies in balancing the complex nature of bronchiectasis with the development of effective treatments.
What do you think? Are the current treatment guidelines sufficient, or do we need more targeted approaches? Share your thoughts in the comments, and let's continue the conversation on improving bronchiectasis management.
